Metixene

Oral
Monotherapy in Parkinson's disease

Closed-angle glaucoma, myasthenia gravis; paralytic ileus; pyloric stenosis and prostatic hyperplasia; hyperthyroidism; tachycardia.

Down's syndrome. Child. Acute MI; cardiac insufficiency; pyrexia. Severe hepatic impairment and renal failure. Pregnancy and lactation.

Dryness of the mouth, constipation, nausea, asthenia, vertigo, blurred vision, ataxia, fever, headache, rash, acute glaucoma.

Symptoms: Dilated and sluggish pupils, warm and dry skin, facial flushing, dryness of mouth, pharynx, nose and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, seizures.

Effects may be enhanced by other drugs with antimuscarinic properties e.g. amantadine, antihistamines, phenothiazine antipsychotics and TCAs. MAOIs may possibly enhance antimuscarinic effects. May affect the absorption of other drugs. Antimuscarinics and parasympathomimetics may counteract each other's effects.

Description: Metixene is a tertiary antimuscarinic with both central and peripheral actions. It also has antihistaminic and direct antispasmodic effects.
Pharmacokinetics:
Absorption: Absorbed from the GI tract.
Metabolism: Hepatic via sulfoxydation and N-demethylation.
Excretion: Via urine.

Antiparkinsonian Drugs